Loading
A phase 3 trial of Magrolimab, Venetoclax and Azacitidine in Acute myeloid leukaemia, run by Gilead Sciences, recorded as terminated on the registry.
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT05079230 by Gilead Sciences, with 378 participants recorded, started 2022-07-07 and due to reach its primary completion in 2024-04-11. Interventions recorded: Magrolimab, Venetoclax, Azacitidine, Placebo. Conditions recorded: Acute Myeloid Leukemia.
Linked to the drug Magrolimab because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
378 enrolled.
95% CI 8.7 to 14.9; Figures from the ClinicalTrials.gov results section (first posted 2025-04-04), not from a publication · 95% CI 9.7 to NA
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS)primary | Magrolimab + Venetoclax + Azacitidine | 189 | 10.7 months | 1.178 (0.848 to 1.637) | 0.3276 | link |
| Magrolimab Matching Placebo + Venetoclax + Azacitidine | 189 | 14.1 months |
Shares Magrolimab, Gilead Sciences (incl. Kite), Azacitidine, Venetoclax and the tag pipeline.
Shares Magrolimab, Gilead Sciences (incl. Kite), Azacitidine and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.